Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Use of Vasopressin in Septic Shock.
Jamil Cedeño Mora
1,200 participants
Oct 1, 2025
OBSERVATIONAL
Conditions
Summary
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.
Eligibility
Inclusion Criteria14
- Eligible patients for this study must comply with the following requirements.
- ICU admission with a septic shock diagnosis.
- Age 18 years or above at ICU admission.
- Use of vasopressin as an adjunct of norepinephrine.
- For the purposes of this study, septic shock is defined by full compliance with the following criteria.
- Sustained arterial hypotension or serum lactate above 2 mmol/L.
- Adequate but unsuccessful fluid resuscitation.
- Vasopressor usage to maintain a mean arterial pressure above 65 mmHg.
- Probable or proven infectious etiology.
- Patients with some of the following conditions will be automatically excluded.
- Pregnancy.
- Ischemic cardiogenic shock.
- Acute intestinal ischemia.
- Readmission to the Intensive Care Unit.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A state-of-the-art line of research in septic shock management focuses on the potential use of a second vasopressor agent. Current efforts aim to determine which drug should be used and the optimal timing for its initiation. In line with this, the Surviving Sepsis Campaign 2021 clinical guide recommends considering vasopressin-arginine (VAP) as a second-line vasopressor when norepinephrine (NAD) doses exceed 0.25 µg/kg/min, although this suggestion is based on limited evidence and remains weak.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07255378